Physician profile
Isaac Kim
NPI 1235217985
$34,551.39
in general payments reported to CMS, 2019-2025
13 companies · $9,069 in 2025
The $9,069 reported for 2025 was more than what 93% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $205 · 2021: $56.37 · 2022: $4,536 · 2023: $3,455 · 2024: $4,757 · 2025: $9,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,250 · Consulting Fee: $5,240 · Travel and Lodging: $2,193 · Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,250.00 |
| Consulting Fee | $5,240.00 |
| Travel and Lodging | $2,193.27 |
| Food and Beverage | $1,597.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $18,676.24 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $7,024.84 | 2022-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $5,739.90 | 2019 | |
| Janssen Global Services, LLC | $1,204.54 | 2019 | |
| Janssen Research & Development, LLC | $600.00 | 2023 | |
| Dendreon Pharmaceuticals LLC | $347.25 | 2022-2023 | Provenge |
| Boston Scientific Corporation | $259.80 | 2019-2025 | Ams 700, General - Therapies |
| Conmed Corporation | $244.05 | 2020-2022 | |
| Janssen Biotech, INC. | $145.30 | 2022-2025 | Erleada |
| Medtronic, INC. | $138.13 | 2025 | Inceptiv |
| Astellas Pharma US INC | $61.02 | 2023 | Xtandi |
| Ambu INC. | $56.37 | 2021 | |
| Medela LLC | $53.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.